



About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc., is a privately held pharmaceutical company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. Founded in 2002, Cornerstone is headquartered in Cranbury, New Jersey with laboratories in both Cranbury and in Stony Brook, NY.

Cornerstone currently has a drug in clinical trials targeting certain key enzymes crucial to cancer cell metabolism. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated. Its lead drug, CPI-613, is currently being evaluated in three ongoing Phase I and Phase I/II clinical trials in a variety of tumor types. In addition, Cornerstone has an exciting drug-delivery technology in development. Emulsiphan deposits cancer-fighting drugs directly into cancer cells (not just tumor mass) by focusing on the distinct metabolism of these cells.

In November of 2009, Cornerstone's CPI-613, was named one of the "top most interesting oncology projects available for partnering" by Windhover Information. The U.S. National Cancer Institute (NCI) entered a Collaboration Agreement with Cornerstone in March 2010 for the use of Emulsiphan with some of NCI's novel agents. The agreement calls for Cornerstone to apply its proprietary Emulsiphan cancer selective delivery nanotechnology platform to a class of agents developed at the NCI's Center for Cancer Research and Nanobiology Program.

Cornerstone is a forerunner in the cancer metabolism space. The company has a significant lead on other companies targeting certain aspects of cancer metabolism:

- The company has multiple technologies, which include lead drug candidate, CPI-613 and drug delivery platform, Emulsiphan
- Cornerstone has a drug in human testing (three clinical trials ongoing)
- Cornerstone has been researching cancer metabolism as a company since its launch in 2002, with its founders studying this area far longer in prior commercial and academic settings
- Cornerstone has kept its know-how in house and has a proprietary position on its drug candidates
- Cornerstone's most advanced drug has a unique target and mechanism of action

Company Leadership

Cornerstone's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development.

Management

Cornerstone's management team is led by CEO Rob Shorr, Ph.D., who began his career at



Smithkline & French (now GSK.) He was Chief Scientist at Enzon (ENZN) and at United Therapeutics (UTHR) prior to co-founding Cornerstone. Dr. Shorr has published extensively and won numerous awards for his research in cancer and drug delivery.

Scientific Advisory Board

Paul Bingham, Ph.D. and Zuzana Zachar, Ph.D. have been focused on targeting cancer metabolism since the mid 1990's. Gregg Semenza, Ph.D. is an acknowledged world leader in the space and discovered Hypoxia Inducible Factor 1 (HIF1). Robert Weinberg, Ph.D., one of the leading cancer researchers in the world and credited with the discovery of the oncogene, provides significant expertise as a scientific advisor.

For more information please visit www.cornerstonepharma.com or contact Meghan Weber at (917) 399-8713